CpG oligonucleotides as immune adjuvants.
Krieg
A M
AM
University of Iowa, Department of Internal Medicine, Iowa City 52242, USA.
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000235:genetics / Q000494:pharmacology*; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D001483:Base Sequence; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D018899:CpG Islands; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D009838:Oligodeoxyribonucleotides / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D016207:Cytokines; D009838:Oligodeoxyribonucleotides; D019444:Vaccines, DNA